Trevi Therapeutics
Update in progressTRVI (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on treatments for chronic cough in IPF and other interstitial lung diseases, including refractory cough. It develops Haduvio, an oral extended-release nalbuphine formulation, in a phase 2b trial for IPF-related cough and a phase 2a trial for refractory cough. It has a license with Keenova Therapeutics plc. Founded in 2011 and based in New Haven, Connecticut.
Company score
- Sentiment
- 0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMs. Jennifer L. Good
- Founded2011
- Employees34
- Websitewww.trevitherapeutics.com
Identifiers
- ISINUS89532M1018
- FIGIBBG003QGQRB9
- CUSIP89532M101
- CIK0001563880